Trihexyphenidyl hydrochloride - Generic Drug Details

What are the generic sources for trihexyphenidyl hydrochloride and what is the scope of patent protection?

Trihexyphenidyl hydrochloride is the generic ingredient in three branded drugs marketed by Lederle, Chartwell Rx, Pharm Assoc, Pharm Ventures, Schering, Hikma, Natco Pharma Ltd, Novitium Pharma, Nylos, Vangard, and Watson Labs, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for trihexyphenidyl hydrochloride. Eight suppliers are listed for this compound.

Summary for trihexyphenidyl hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	11
NDAs:	16
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	6
What excipients (inactive ingredients) are in trihexyphenidyl hydrochloride?	trihexyphenidyl hydrochloride excipients list
DailyMed Link:	trihexyphenidyl hydrochloride at DailyMed

Recent Clinical Trials for trihexyphenidyl hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Deepak K. Sarpal, M.D.	PHASE4
National Institute of Mental Health (NIMH)	PHASE4
Children's Mercy Hospital Kansas City	PHASE1

See all trihexyphenidyl hydrochloride clinical trials

Medical Subject Heading (MeSH) Categories for trihexyphenidyl hydrochloride

Antiparkinson Agents

Muscarinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for trihexyphenidyl hydrochloride

N04AA	Tertiary amines
N04A	ANTICHOLINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

US Patents and Regulatory Information for trihexyphenidyl hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	TRIHEXYPHENIDYL HYDROCHLORIDE	trihexyphenidyl hydrochloride	TABLET;ORAL	085117-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	TRIHEXYPHENIDYL HYDROCHLORIDE	trihexyphenidyl hydrochloride	TABLET;ORAL	084363-001	Approved Prior to Jan 1, 1982	AA	RX	No	Yes
Nylos	TRIHEXYPHENIDYL HYDROCHLORIDE	trihexyphenidyl hydrochloride	TABLET;ORAL	085622-001	Approved Prior to Jan 1, 1982		DISCN	No	No

TRIHEXYPHENIDYL HYDROCHLORIDE: MARKET DYNAMICS AND FINANCIAL TRAJECTORY

Last updated: February 19, 2026

Trihexyphenidyl hydrochloride is an anticholinergic medication primarily used for the symptomatic treatment of Parkinson's disease and drug-induced extrapyramidal symptoms. Its market dynamics are shaped by patient demographics, treatment guidelines, generic competition, and evolving therapeutic landscapes. The financial trajectory of drugs like trihexyphenidyl hydrochloride is influenced by manufacturing costs, pricing strategies, market penetration, and patent expiry.

What is the current therapeutic landscape for Parkinson's disease and related disorders?

The therapeutic landscape for Parkinson's disease (PD) and related disorders is characterized by a multi-faceted approach targeting symptom management and, increasingly, disease modification.

• Symptomatic Management:

  • Levodopa/Carbidopa: Remains the gold standard for motor symptom control, particularly bradykinesia and rigidity [1]. However, long-term use is associated with motor fluctuations and dyskinesias.
  • Dopamine Agonists: Pramipexole, ropinirole, rotigotine, and apomorphine provide dopaminergic stimulation and are used as initial therapy or adjuncts to levodopa.
  • MAO-B Inhibitors: Selegiline and rasagiline can be used in early PD or as adjuncts, inhibiting the breakdown of dopamine.
  • COMT Inhibitors: Entacapone and tolcapone are used to prolong the effect of levodopa by inhibiting its peripheral breakdown.
  • Amantadine: Primarily used for dyskinesias and mild motor symptoms.
  • Anticholinergics: Trihexyphenidyl hydrochloride and benztropine are historically used to manage tremor and rigidity, particularly in younger patients, but their use has declined due to side effects like cognitive impairment [2].

• Non-Motor Symptoms: Growing emphasis is placed on managing non-motor symptoms, including depression, anxiety, sleep disorders, cognitive impairment, and autonomic dysfunction. These often significantly impact quality of life.

• Disease Modification: The pursuit of disease-modifying therapies (DMTs) is a major research focus. Current treatments primarily manage symptoms without slowing or reversing neurodegeneration. Investigational approaches target alpha-synuclein aggregation, neuroinflammation, and mitochondrial dysfunction.

• Emerging Therapies:

  • Gene Therapy: Investigational approaches aim to deliver genes that can enhance dopamine production or neurotrophic factors.
  • Cell-Based Therapies: Stem cell research for replacing lost dopaminergic neurons continues.
  • New Drug Targets: Research into novel pathways and targets beyond dopaminergic systems is ongoing.

The use of trihexyphenidyl hydrochloride has decreased in recent years due to the availability of more targeted and effective treatments for motor symptoms, as well as concerns about its anticholinergic side effects, particularly in older adult populations where cognitive function is already a concern [3].

What are the primary indications and off-label uses for Trihexyphenidyl Hydrochloride?

Trihexyphenidyl hydrochloride's established indications and observed off-label uses reflect its pharmacological profile as an anticholinergic agent.

Primary Indications:

• Parkinson's Disease: Symptomatic treatment of tremor and rigidity. Historically, it was a cornerstone therapy, particularly in younger patients experiencing these symptoms. Its role has diminished with the advent of more effective dopaminergic agents and concerns over anticholinergic burden.
• Drug-Induced Extrapyramidal Symptoms (EPS): Management of involuntary movements (dystonia, akathisia, parkinsonism) caused by antipsychotic medications. This remains a significant, though often secondary, indication.

Off-Label Uses:

• Tardive Dyskinesia (TD): While not a primary indication, it may be used to manage certain hyperkinetic movements associated with TD, although evidence for efficacy is mixed and other agents are generally preferred.
• Muscle Spasms: Can be used to alleviate certain types of muscle spasms unrelated to neurological parkinsonism.
• Gastrointestinal Disorders: Occasionally used off-label for conditions involving smooth muscle spasms in the GI tract, leveraging its antispasmodic properties.
• Hyperhidrosis (Excessive Sweating): Its anticholinergic action can reduce sweating, leading to off-label use for severe hyperhidrosis in some cases.

The utility of trihexyphenidyl hydrochloride in these off-label scenarios is often considered when standard treatments are ineffective or contraindicated, or as an adjunctive therapy.

What is the global market size and projected growth for Trihexyphenidyl Hydrochloride?

The global market for trihexyphenidyl hydrochloride is characterized by a mature, primarily generic landscape, with its market size and growth trajectory influenced by demand in its niche indications and the availability of competing therapies.

• Market Size: Precise global market figures for trihexyphenidyl hydrochloride alone are not readily available in public market research reports, as it is often grouped within broader categories such as "Parkinson's disease drugs," "Anticholinergics," or "CNS drugs." However, based on its established usage and the size of the generic drug market, it is estimated to be in the tens to low hundreds of millions of US dollars annually. This figure is significantly lower than newer, branded therapies for Parkinson's disease.

• Market Trends and Growth Projection:

  • Declining Growth: The market for trihexyphenidyl hydrochloride is generally considered stagnant to declining. Several factors contribute to this:

    • Erosion by Newer Therapies: The development of more effective and safer treatments for Parkinson's disease, such as levodopa-based therapies and dopamine agonists, has reduced the reliance on older anticholinergics.
    • Side Effect Profile: Concerns over anticholinergic side effects, including cognitive impairment, dry mouth, constipation, and blurred vision, particularly in the aging population, limit its use.
    • Shift in Treatment Paradigms: The focus is shifting towards disease modification and comprehensive management of both motor and non-motor symptoms, areas where trihexyphenidyl hydrochloride offers limited benefit.
    • Genericization: The drug has long been off-patent, leading to intense price competition among generic manufacturers. This suppresses overall market revenue growth.

  • Niche Demand: Despite the overall decline, a consistent, albeit shrinking, demand exists for:

    • Drug-Induced EPS: Where it remains a viable treatment option.
    • Specific Patient Subgroups: Patients who respond well to anticholinergics and tolerate the side effects, or those for whom other treatments are contraindicated or ineffective.
    • Cost-Effectiveness in Developing Markets: In regions with limited healthcare budgets, generic trihexyphenidyl hydrochloride may remain a cost-effective option for managing certain symptoms.

  • Projected Trajectory: The market is expected to continue a low single-digit percentage decline annually over the next five to ten years. Growth in specific emerging markets or for niche off-label uses would be marginal and unlikely to offset the decline in established markets and indications.

The financial trajectory is therefore characterized by volume-driven sales in a highly competitive generic environment, with pricing pressure and a shrinking patient base for its primary indication.

Who are the key manufacturers and suppliers of Trihexyphenidyl Hydrochloride?

The market for trihexyphenidyl hydrochloride is populated by numerous generic pharmaceutical manufacturers and suppliers globally. Due to its status as an established, off-patent drug, competition is robust. Identifying a definitive "key" manufacturer is challenging as production is distributed among many entities. However, prominent players often include:

• Major Generic Drug Manufacturers: Companies with broad portfolios of generic central nervous system (CNS) medications are typically involved in producing trihexyphenidyl hydrochloride. Examples of such companies historically and currently involved in generic APIs and finished dosage forms include:

  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Actavis plc (now part of Teva)
  • Mylan N.V. (now part of Viatris)

• Specialty API Manufacturers: Some companies focus on the Active Pharmaceutical Ingredient (API) production of older, well-established drugs. These APIs are then sold to formulation companies worldwide.

• Regional Manufacturers: In specific geographic regions, local manufacturers may hold significant market share due to established distribution networks and local regulatory approvals.

• Wholesalers and Distributors: A vast network of pharmaceutical wholesalers and distributors plays a crucial role in disseminating the product to pharmacies and healthcare facilities.

The landscape is characterized by a high degree of fragmentation. Manufacturers compete primarily on price, quality, and supply chain reliability. The focus for these companies is on efficient, high-volume production of the generic API and finished dosage forms.

What is the patent and regulatory status of Trihexyphenidyl Hydrochloride?

Trihexyphenidyl hydrochloride is a well-established drug with a long history of market availability. Its patent and regulatory status reflects this maturity.

• Patent Expiry: Trihexyphenidyl hydrochloride is long off-patent. The original patents protecting its composition of matter and initial therapeutic uses expired decades ago. There are no active, core composition of matter patents that would prevent generic manufacturers from producing and selling the drug.

• Regulatory Status:

  • FDA (United States): Trihexyphenidyl hydrochloride is approved by the U.S. Food and Drug Administration (FDA) for its indicated uses. It is available as a prescription drug. It is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), indicating that generic versions are available and considered therapeutically equivalent to the reference listed drug.
  • EMA (European Union): Similar to the FDA, trihexyphenidyl hydrochloride is authorized for marketing in various European Union member states by national competent authorities. It is available under different brand names and as generics.
  • Other Regulatory Bodies: It is approved and available in many other countries worldwide, regulated by their respective national health authorities.

• Exclusivity: Given the lack of patent protection, there is no market exclusivity based on patents. Exclusivity, if any, would stem from the initial reference drug designation or specific regulatory designations that are unlikely to apply to such an old compound.

• New Drug Applications (NDAs) / Generics: Manufacturers seeking to market generic versions must file Abbreviated New Drug Applications (ANDAs) with the FDA (or equivalent filings in other regions), demonstrating bioequivalence and pharmaceutical equivalence to the reference drug.

The regulatory pathway for trihexyphenidyl hydrochloride is largely defined by established generic drug approval processes, emphasizing quality, safety, and bioequivalence rather than novel intellectual property.

What are the pricing dynamics and revenue potential for Trihexyphenidyl Hydrochloride?

The pricing dynamics and revenue potential for trihexyphenidyl hydrochloride are characteristic of a mature, genericized pharmaceutical product with a declining primary indication.

• Pricing Dynamics:

  • Generic Price Competition: The most significant factor influencing pricing is intense competition among numerous generic manufacturers. This has driven prices down to very low levels.
  • Volume-Based Sales: Manufacturers primarily achieve revenue through high-volume sales rather than high per-unit pricing.
  • Wholesale Acquisition Cost (WAC): The WAC for a bottle of 100 tablets (e.g., 2 mg or 5 mg) can range from $10 to $50, depending on the manufacturer, distributor, and contractual agreements. This is a fraction of the cost of branded, newer Parkinson's medications.
  • Payer Influence: Pharmacy benefit managers (PBMs) and insurance formularies often favor the lowest-cost generic options, further exerting downward pressure on prices.
  • API Costs: Manufacturing costs, particularly the cost of the API, are relatively low for trihexyphenidyl hydrochloride due to established synthetic routes and economies of scale.

• Revenue Potential:

  • Limited Growth Potential: The overall revenue potential for trihexyphenidyl hydrochloride is limited and likely declining.
  • Market Share Stability (for Generics): While the overall market size may shrink, individual generic manufacturers can maintain or slightly increase revenue by capturing market share from competitors through competitive pricing, reliable supply, and strong distribution channels.
  • Niche Market Sustenance: Revenue is sustained by demand in specific niches, such as drug-induced EPS and certain patient populations who continue to benefit from or tolerate the drug.
  • Regional Variations: Revenue potential can vary by region, with developing markets potentially offering more stable, albeit lower, revenue streams due to cost considerations.
  • Estimated Annual Revenue: As mentioned earlier, the total global market value is estimated in the tens to low hundreds of millions of US dollars. This revenue is fragmented across many manufacturers and suppliers. A single manufacturer's revenue from this product would typically be a small fraction of their total sales unless they hold a dominant share of a very specific niche.

The revenue model for trihexyphenidyl hydrochloride is thus one of volume, cost efficiency, and competitive pricing in a mature generic market, rather than innovation-driven growth or premium pricing.

What are the manufacturing considerations and supply chain challenges?

Manufacturing trihexyphenidyl hydrochloride involves standard pharmaceutical production processes, but like any drug, it faces supply chain considerations and potential challenges.

• Manufacturing Process:

  • Active Pharmaceutical Ingredient (API) Synthesis: The synthesis of trihexyphenidyl hydrochloride is a well-established multi-step chemical process. Manufacturers require facilities compliant with Current Good Manufacturing Practices (cGMP). The primary synthesis typically involves reacting a Grignard reagent with a suitable ester, followed by hydrochloride salt formation.
  • Formulation: The API is then formulated into finished dosage forms, primarily oral tablets, and sometimes oral solutions. This involves blending the API with excipients (binders, fillers, disintegrants, lubricants) and compressing the mixture into tablets.
  • Quality Control: Rigorous quality control testing is performed at each stage, from raw materials and in-process samples to the finished product, to ensure identity, purity, potency, and dissolution characteristics.

• Supply Chain Considerations:

  • Raw Material Sourcing: Manufacturers must secure reliable sources for key chemical precursors used in API synthesis. Geopolitical stability, supplier capacity, and quality of these raw materials are critical.
  • API Production Capacity: Sufficient API production capacity is needed to meet global demand. Many generic API manufacturers operate on large scales to achieve cost efficiencies.
  • Finished Dosage Form Manufacturing: Having adequate capacity for tableting, packaging, and labeling is essential.
  • Distribution Networks: Establishing and maintaining robust distribution networks to reach pharmacies, hospitals, and other healthcare providers globally is vital. This involves logistics, warehousing, and compliance with transportation regulations.

• Potential Supply Chain Challenges:

  • API Shortages: While less common for older drugs like trihexyphenidyl hydrochloride compared to novel therapeutics, shortages can arise due to:
    • Manufacturing issues at a major API supplier.
    • Disruptions in raw material supply.
    • Regulatory enforcement actions against a key manufacturer.
    • Sudden spikes in demand (though unlikely for this drug).
  • Quality Control Failures: A single batch failure or a recall due to quality issues at an API or finished product manufacturer can disrupt supply.
  • Regulatory Hurdles: Changes in regulatory requirements or inspection failures can temporarily halt production or distribution.
  • Geopolitical Risks: Trade disputes, tariffs, or political instability in regions where key raw materials are sourced or manufacturing occurs can impact supply.
  • Logistical Disruptions: Issues with shipping, customs clearance, or pandemics can impede the timely delivery of finished products.
  • Intense Price Competition Impacting Viability: The low profitability of the drug can sometimes lead smaller manufacturers to exit the market or reduce production, potentially impacting overall supply stability.

Manufacturers must maintain diversified sourcing strategies, robust quality management systems, and strong relationships with distributors to mitigate these challenges and ensure consistent product availability.

What is the competitive landscape and threat of new entrants?

The competitive landscape for trihexyphenidyl hydrochloride is highly mature and characterized by a strong presence of generic manufacturers. The threat of new entrants, in the traditional sense of novel drug development, is effectively non-existent.

• Competitive Landscape:

  • Generic Domination: The market is entirely dominated by generic manufacturers. There are no branded versions of trihexyphenidyl hydrochloride with significant market share in major developed markets.
  • Price-Based Competition: Competition is primarily driven by price. Manufacturers continuously strive to lower production costs to offer the most competitive pricing.
  • Market Share Erosion: Competitors vie for market share by offering slightly lower prices, ensuring consistent supply, and maintaining high-quality standards.
  • Established Players: Large, established generic pharmaceutical companies with global reach and efficient manufacturing operations hold significant market share. Smaller regional players also exist.
  • API Suppliers: Competition also exists among API suppliers, influencing the cost structure for finished dosage form manufacturers.

• Threat of New Entrants:

  • Low Threat for New Branded Drugs: The threat of a new branded drug entering the market to compete with trihexyphenidyl hydrochloride for its primary indications is extremely low. Given the advancements in Parkinson's disease treatment and the challenges in developing disease-modifying therapies, any new entrant would likely focus on novel mechanisms or disease modification, not direct competition with an old symptomatic treatment.
  • Moderate Threat for New Generic Entrants: The threat of new generic manufacturers entering the market is moderate but limited.
    • Barriers to Entry: The primary barriers to entry for generic manufacturers are:
      • Established Supply Chains: Existing manufacturers have well-developed supply chains and distribution networks.
      • Economies of Scale: Large-scale production provides cost advantages that are difficult for new, smaller entrants to match.
      • Regulatory Navigation: While generics are a known path, navigating FDA ANDA approvals (or equivalents) still requires expertise and investment.
      • Low Profit Margins: The razor-thin profit margins on trihexyphenidyl hydrochloride make it less attractive for new companies to invest in setting up production facilities and entering the market. Investment might be better directed towards higher-margin products.
    • Potential for Niche Entry: A new entrant might emerge if they can offer a specific advantage, such as a more cost-effective API synthesis route, superior tablet manufacturing quality, or a unique distribution agreement in a specific region. However, the overall market size and profitability limit the attractiveness of such ventures.

In essence, the competitive landscape is saturated with generics, and the primary "competition" comes from alternative, more modern therapeutic options rather than new entrants to the trihexyphenidyl hydrochloride market itself.

Key Takeaways

• Trihexyphenidyl hydrochloride is a mature, genericized anticholinergic medication with diminishing primary use in Parkinson's disease due to the availability of superior therapies.
• Its main current indications are symptomatic treatment of Parkinson's disease (primarily tremor and rigidity) and drug-induced extrapyramidal symptoms.
• The global market size is estimated in the tens to low hundreds of millions of US dollars, characterized by a mature, stagnant to declining trajectory driven by generic competition and reduced demand in its primary indication.
• The market is populated by numerous generic manufacturers, with competition centered on price, volume, and supply chain reliability.
• The drug is long off-patent, and no significant new intellectual property is expected.
• Pricing is highly competitive, with low per-unit costs contributing to limited overall revenue potential.
• Manufacturing involves standard API synthesis and formulation, with supply chain challenges primarily related to raw material sourcing, quality control, and logistical disruptions.
• The threat of new generic entrants exists but is moderate due to established competition, economies of scale, and low profit margins. The threat of new branded therapeutic alternatives is significantly higher and is the primary driver of market evolution.

Frequently Asked Questions

What is the typical daily dosage of Trihexyphenidyl Hydrochloride for Parkinson's disease?

Typical initial dosages for Parkinson's disease range from 1 mg to 2 mg per day, with gradual increases to 5 mg to 15 mg per day, divided into three or four doses. The maximum recommended daily dose is generally 15 mg [4]. Dosage must be individualized based on patient response and tolerability.

What are the most common side effects of Trihexyphenidyl Hydrochloride?

Common anticholinergic side effects include dry mouth, blurred vision, constipation, urinary retention, and drowsiness. Cognitive impairment, confusion, and memory disturbances can also occur, particularly in older adults [2, 5].

Can Trihexyphenidyl Hydrochloride be used in combination with Levodopa?

Yes, Trihexyphenidyl hydrochloride can be used in combination with Levodopa, particularly for patients experiencing persistent tremor or rigidity that is not adequately controlled by Levodopa alone. However, its use in combination may exacerbate certain side effects, and close monitoring is necessary [1].

Is Trihexyphenidyl Hydrochloride still a first-line treatment for Parkinson's disease?

No, Trihexyphenidyl hydrochloride is not considered a first-line treatment for Parkinson's disease. Levodopa/carbidopa and dopamine agonists are typically preferred as initial therapies due to their greater efficacy in managing motor symptoms and generally better tolerability profiles in the long term [1, 3].

What are the contraindications for using Trihexyphenidyl Hydrochloride?

Trihexyphenidyl hydrochloride is contraindicated in patients with known hypersensitivity to the drug. It should also be used with extreme caution or avoided in patients with glaucoma (especially narrow-angle glaucoma), pyloric or duodenal obstruction, achalasia, paralytic ileus, and myasthenia gravis, or in the elderly who may be more susceptible to its anticholinergic effects [4, 5].

Citations

1. Olanow, C. W., & Poewe, W. (2014). Management of Parkinson's disease: a review of the past decade and future prospects. Movement Disorders, 29(10), 1216-1232.
2. Piazzini, D. B., & Tassorelli, C. (2021). Parkinson's Disease: Diagnosis and Therapeutics. Seminars in Neurology, 41(05), 619-630.
3. World Health Organization. (2019). Parkinson disease. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
4. U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases (Note: Specific drug product information is queried through the database, not a static document).
5. National Institute of Neurological Disorders and Stroke. (n.d.). Parkinson's Disease: Hope Through Research. Retrieved from https://www.ninds.nih.gov/Disorders/All-Disorders/Parkinsons-Disease-Hope-Through-Research